Semaglutide causes gastrointestinal side effects in a significant number of users, with nausea affecting roughly 23% of people and vomiting around 9%. Most of these effects are mild to moderate and tend to ease as the body adjusts, but some rarer complications deserve attention before starting treatment.
Why Semaglutide Causes Side Effects
Semaglutide mimics a natural hormone called GLP-1 that your body releases after eating. This hormone activates receptors in three key areas: the pancreas (triggering insulin release), the brain’s satiety centers (reducing appetite), and the nerves controlling your stomach (slowing digestion). That slowdown in gastric emptying is what makes you feel full longer, which helps with weight loss and blood sugar control. It’s also the primary reason so many side effects center on the gut.
Common Digestive Side Effects
Digestive issues are by far the most frequent complaint. A meta-analysis of randomized controlled trials found the following incidence rates for people taking GLP-1 receptor agonists compared to placebo:
- Nausea: 22.8% of users, roughly three times the rate seen with placebo
- Diarrhea: 13%, about twice the placebo rate
- Vomiting: 9.1%, 3.6 times the placebo rate
- Constipation: 7.4%, about 2.4 times the placebo rate
- Decreased appetite: 2.6%, 3.5 times the placebo rate
These symptoms are most common during the dose-escalation phase, the first several weeks when your dose is gradually increased. Many people find that nausea and vomiting settle down once they reach a stable dose. Eating smaller, more frequent meals rather than three large ones can help. Sipping cold, clear fluids between meals (rather than during them) and choosing easy-to-digest foods like broths and soups also reduce discomfort. Eating slowly and stopping as soon as you feel satisfied makes a noticeable difference when your stomach is emptying more slowly than usual.
Gallbladder Problems
Semaglutide raises the risk of gallbladder-related events. In clinical trials, 3% of semaglutide users experienced gallbladder problems compared to 2.2% on placebo, a statistically significant increase. Gallstones specifically occurred in 2.3% of semaglutide users versus 0.9% on placebo, making the risk roughly 2.5 times higher. Rapid weight loss from any cause is a well-known trigger for gallstones, so this finding isn’t entirely surprising, but it’s worth being aware of. Symptoms to watch for include sudden, intense pain in the upper right abdomen, nausea after fatty meals, and pain that radiates to your back or right shoulder.
Gastroparesis and Bowel Obstruction
A University of British Columbia study examining health insurance records for roughly 16 million U.S. patients found that GLP-1 agonists were associated with a 3.67 times higher risk of gastroparesis (stomach paralysis) and a 4.22 times higher risk of bowel obstruction compared to another weight-loss medication. These are uncommon complications, but they’re serious. Gastroparesis means the stomach loses its ability to move food into the small intestine normally, causing persistent vomiting, nausea, and abdominal pain. Bowel obstruction produces cramping, bloating, and vomiting. Neither condition is currently listed on product warning labels, though researchers have urged regulatory agencies to update them.
Pancreatitis Risk
Pancreatitis, or inflammation of the pancreas, is listed as a potential risk on semaglutide’s label. However, the actual data is reassuring. In pooled clinical trials of people without diabetes, pancreatitis occurred in 0.20% of semaglutide users and 0.26% of those on placebo, with no statistically significant difference between the groups. That said, anyone with a history of pancreatitis should discuss this with their prescriber, and severe, persistent abdominal pain that radiates to the back warrants prompt medical attention.
Muscle and Lean Mass Loss
One of the more concerning findings involves body composition. In the STEP-1 trial, participants lost an average of 15.3 kg (about 34 pounds) on semaglutide, but 6.92 kg of that (roughly 45%) came from lean mass rather than fat. This significantly exceeds what researchers call the “quarter fat-free mass rule,” which predicts that about one-fourth of weight lost should come from lean tissue. Lean mass includes muscle, bone, and organ tissue, and losing too much can reduce strength, lower your metabolic rate, and increase the risk of frailty, especially in older adults. Resistance training and adequate protein intake during treatment are the main strategies for preserving muscle while losing fat.
Low Blood Sugar
Semaglutide on its own carries a low risk of hypoglycemia because it stimulates insulin release in a glucose-dependent way, meaning it primarily works when blood sugar is already elevated. Clinical trials have shown that mild hypoglycemia sometimes occurs during dose escalation but tends to resolve at stable doses. The real risk comes when semaglutide is combined with insulin or medications that independently lower blood sugar. In those cases, doses of the other medications often need to be reduced to prevent dangerous drops.
Thyroid Cancer Warning
Semaglutide carries an FDA boxed warning, the most serious type of safety alert, regarding thyroid tumors. In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. Whether this translates to humans remains uncertain, but the FDA considers it significant enough to contraindicate semaglutide in anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN2). If you have either of these in your background, semaglutide is not an option.
Eye Complications in People With Diabetes
In the SUSTAIN-6 trial, semaglutide users with type 2 diabetes had a 76% higher rate of diabetic retinopathy complications compared to placebo. This appears to be related to how quickly blood sugar drops rather than a direct effect of the drug itself. Rapid improvements in blood sugar control have long been associated with temporary worsening of retinopathy in people who already have eye damage from diabetes. A large retrospective study of over 810,000 semaglutide users found no increased risk of serious eye complications compared to other diabetes medications, and semaglutide actually showed lower rates of treatment-requiring retinopathy than several alternatives. Still, if you have existing diabetic eye disease, more frequent eye exams during the first year of treatment are a reasonable precaution.